Spear Bio key facts
- Developer of ultrasensitive protein detection technology designed to offer significant benefits across the healthcare value chain.
- Spear Bio’s last known valuation is $134.0M.
- It has raised $69.8M across 4 recorded rounds; the latest was Early Stage VC ($45.0M) in Jul 2024.
- Notable investors include Hongshan Capital Group, CDH Investments, Yonghua Capital, Foresite Capital, Maverick Ventures — 9 tracked in total.
- Spear Bio has filed 4 Form Ds with the SEC since 2021, most recently Aug 2024 ($45.0M sold to 8 investors).
- Status: Privately Held (backing).
- ·Watch Spear Bio: the Monday email on marks, rounds and moves
Spear Bio funding rounds
4 roundsSpear Bio valuation
Spear Bio's last known valuation is $134 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Spear Bio raised?
Spear Bio has raised $69.8 million across 4 recorded rounds since 2021. The largest was a $45 million early-stage round in Jul 2024.
Spear Bio has filed 4 Form Ds with the SEC since 2021, most recently in Aug 2024 ($45 million sold to 8 investors).
Spear Bio investors
9 investors are on record for Spear Bio, including Hongshan Capital Group, CDH Investments, Yonghua Capital and Foresite Capital. The early-stage round in Jul 2024 drew 8 investors.
About Spear Bio
Developer of ultrasensitive protein detection technology designed to offer significant benefits across the healthcare value chain. The company's technology helps in self-testing and telemedicine-based diagnostics that rely on the ability to quantify minuscule amounts of protein biomarkers from at-home collected samples, enabling clinicians with ultrasensitive detection from small sample volumes that fit into existing workflows for sample collection, processing, and detection.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2021
- Employees
- 48
- Website
- spear.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Spear Bio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.